Capstone Investment Advisors LLC Boosts Holdings in RxSight, Inc. (NASDAQ:RXST)

Capstone Investment Advisors LLC raised its stake in shares of RxSight, Inc. (NASDAQ:RXST) by 698.4% in the 1st quarter, Holdings Channel reports. The firm owned 127,200 shares of the company’s stock after acquiring an additional 111,269 shares during the period. Capstone Investment Advisors LLC’s holdings in RxSight were worth $6,561,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in RXST. RiverPark Advisors LLC raised its holdings in RxSight by 70.0% during the 4th quarter. RiverPark Advisors LLC now owns 668 shares of the company’s stock valued at $27,000 after buying an additional 275 shares during the period. Amalgamated Bank increased its holdings in shares of RxSight by 7.7% in the 4th quarter. Amalgamated Bank now owns 4,148 shares of the company’s stock valued at $167,000 after acquiring an additional 298 shares during the period. Clear Rock Advisors LLC purchased a new position in RxSight in the fourth quarter valued at about $172,000. Clarus Group Inc. bought a new position in RxSight in the fourth quarter worth about $202,000. Finally, Thompson Davis & CO. Inc. purchased a new stake in shares of RxSight during the fourth quarter valued at about $212,000. Institutional investors own 78.78% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on RXST shares. BTIG Research boosted their target price on RxSight from $61.00 to $72.00 and gave the stock a “buy” rating in a research note on Tuesday, May 7th. Needham & Company LLC upped their price objective on shares of RxSight from $64.00 to $75.00 and gave the company a “buy” rating in a report on Tuesday, May 7th. Oppenheimer increased their price objective on shares of RxSight from $61.00 to $72.00 and gave the company an “outperform” rating in a research report on Tuesday, May 7th. Wells Fargo & Company boosted their target price on shares of RxSight from $61.00 to $68.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 7th. Finally, Stifel Nicolaus lifted their price objective on shares of RxSight from $64.00 to $68.00 and gave the stock a “buy” rating in a research note on Monday, May 6th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, RxSight currently has a consensus rating of “Buy” and a consensus price target of $60.63.

Insiders Place Their Bets

In related news, CEO Ronald M. Md Kurtz sold 40,000 shares of RxSight stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $60.15, for a total value of $2,406,000.00. Following the completion of the transaction, the chief executive officer now owns 764,610 shares in the company, valued at approximately $45,991,291.50. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, Director Julie Andrews sold 15,625 shares of the firm’s stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $58.00, for a total value of $906,250.00. Following the transaction, the director now owns 30,287 shares in the company, valued at $1,756,646. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Ronald M. Md Kurtz sold 40,000 shares of RxSight stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $60.15, for a total transaction of $2,406,000.00. Following the sale, the chief executive officer now directly owns 764,610 shares in the company, valued at approximately $45,991,291.50. The disclosure for this sale can be found here. Over the last quarter, insiders sold 75,625 shares of company stock worth $4,425,250. Company insiders own 9.36% of the company’s stock.

RxSight Stock Down 0.1 %

RxSight stock traded down $0.04 during midday trading on Friday, hitting $56.95. 246,766 shares of the company were exchanged, compared to its average volume of 421,216. RxSight, Inc. has a fifty-two week low of $20.66 and a fifty-two week high of $66.54. The business has a fifty day simple moving average of $58.82 and a two-hundred day simple moving average of $52.41.

RxSight (NASDAQ:RXST) last posted its earnings results on Monday, May 6th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.08). RxSight had a negative net margin of 44.01% and a negative return on equity of 27.68%. The firm had revenue of $29.51 million for the quarter, compared to analysts’ expectations of $27.56 million. During the same period last year, the firm earned ($0.42) earnings per share. RxSight’s revenue for the quarter was up 68.7% compared to the same quarter last year. As a group, sell-side analysts anticipate that RxSight, Inc. will post -0.77 earnings per share for the current year.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.